undamentalytics Newsletter
Sign in

Zevra Therapeutics, Inc. (ZVRA) stock

Add to watchlist

Add holding +

NASDAQ: ZVRA Nasdaq Pharmaceuticals Next results ~November 3, 2026

B Fundamentals grade

Zevra Therapeutics, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$14

Valuation models combined (4)

Base case. Range ~$4.4–$18. Weighted average of 4 models (growth cash-flow model, forward price-to-earnings vs peers, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Zevra Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 6 selling0 purchases and 13 sales by directors and officers, last 12 monthsInsider trades
  • Funds93 adding, 57 cuttingOf 33 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Zevra Therapeutics files

Where Zevra Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $136m, up 119.4% on a year earlier, slower than the 201.3% growth a quarter earlier. Free-cash-flow margin rose to 24.0% from -75.0% a year earlier. Operating margin widened to 60.5% from -192.1%. The diluted share count is up 13.4% on a year earlier, which dilutes existing holders. It passes 7 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $18.44 a share, against a share price of $10.45.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Zevra Therapeutics, Inc.'s trailing-twelve-month revenue grew 119.4% year on year, with a free-cash-flow margin of 24.0%. Where it stands out: operating margin of 60.5% ranks 1 of 67 pharmaceuticals companies we cover. Where it lags: change in growth rate of -81.9pp ranks 70 of 74 pharmaceuticals companies we cover.

Current signal Operating margin expanding: TTM operating margin reached 60.5%, up 252.6pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 119.4% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • High operating margin. 60.5% of revenue is left as operating profit, against a median of -5.9% for pharmaceuticals companies we cover.
  • Margins widening. Operating margin is up 252.6 points on a year ago.
  • Strong cash generation. 24.0% of revenue turned into free cash flow, against a median of 10.1% for pharmaceuticals companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 81.9 points lower than a quarter earlier.
  • Share dilution. Diluted shares rose 13.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 60% and a beta of 0.9 against the S&P 500.
  • Gross margin slipping. Gross margin is down 8.5 points on a year ago.
  • Weak cash conversion. Free cash flow was 56% of net income over the last 12 months.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.25 against an average estimate of $0.18: beat by 41.5%
Revenue
$40m, up 53.3% on a year earlier
Share reaction
+12.9% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 3, 2026; average EPS estimate $0.18

Zevra Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.8%
  • 1 week+6.0%
  • 1 month+1.1%
  • This year+12.7%
  • 1 year-0.8%
  • 5 years+5.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$136M
Operating margin
60.5%
Net margin
42.8%
EPS (TTM, diluted)
$0.97

Growth

Revenue growth
+119.4%
Change in growth rate
−81.9 pts
Share count change
+13.4%

Cash

Free cash flow (TTM)
$32.6M
FCF margin
24.0%
Stock pay % of revenue
9.6%

Earnings

Last results
August 5, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Zevra Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Zevra Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.72 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$17 ~$13–$20 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.5 ~$9.9–$20 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.4 ~$3.8–$11 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$18 ~$15–$21 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$14 ~$4.4–$18 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Zevra Therapeutics, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201520182019202020212022202320242025Now
Share price$317.76$28.48$6.06$11.20$8.71$4.59$6.55$8.34$8.96$10.10
Market value$146m$32m$11m$45m$259m$158m$232m$386m$513m$606m
+ Net debt (− = net cash)−$24m$65m$77m$64m−$112m−$53m−$283000$28m$1m−$145m
Enterprise value$123m$97m$88m$109m$147m$106m$232m$414m$514m$461m
Multiples
Price / sales ——0.9x3.4x9.0x15.6x8.5x16.3x4.8x4.5x
Price / earnings ————————6.2x10.4x
Price / free cash flow ————25.1x————18.6x
EV / EBITDA ————18.4x————5.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

11 /100

Weak moat

How hard Zevra Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -35.4% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -192.1%; its worst year was -323.0%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 2 of 7 years, at a median -75.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 6236.0% over five years; stock-based pay has been a median 23.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (16 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $37m and EPS of $0.18 (range $0.13 to $0.21) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.17 −14% $153m +44%
Next $1.08 −8% $178m +16%

Next year's EPS estimate has moved −51.6% in 90 days, across 3 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −2.0% on 90 days ago. In the last 30 days, 1 analyst raised Zevra Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Zevra Therapeutics, Inc., last 90 days
$1.00 $1.50 $2.00 $2.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.19 Current fiscal year, 60 days ago: $1.25 Current fiscal year, 30 days ago: $1.25 Current fiscal year, 7 days ago: $1.25 Current fiscal year, Now: $1.17 $1.17 Next fiscal year, 90 days ago: $2.23 Next fiscal year, 60 days ago: $1.32 Next fiscal year, 30 days ago: $1.32 Next fiscal year, 7 days ago: $1.10 Next fiscal year, Now: $1.08 $1.08

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.19$2.23
60 days ago $1.25$1.32
30 days ago $1.25$1.32
7 days ago $1.25$1.10
Now $1.17$1.08

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.18 $0.25 +41.5%
Mar 2026 $0.08 $0.18 +114.9%
Dec 2025 $0.04 $0.19 +322.2%
Sept 2025 −$0.02 −$0.01 +50.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

9 analysts, Oct 2026
Buy9100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026279
  2. Sep 2026279
  3. Aug 2026279
  4. Jul 2026279

Counts of recommendations published by analysts covering Zevra Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.6%
of tradable shares
Days to cover
6.56
at average volume
Short interest, 1 month
+8%
to October 15, 2026
Held by institutions
80%
of shares
Held by insiders
1.3%
of shares
Employees
61
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −0.8%

$10.18 on October 31, 2025 to $10.10

ThenNowEffect
Revenue (last 12 months) $62m $136m +119.4%
Net margin 4.3% 42.8% +904.4%
P/E multiple n/m 10.4x −94.9%
Share count 53m 60m −11.8%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ZVRA−22%−47%+43%+27%+7%+13%
Industry peers (median)−18%−52%−14%−2%+9%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ZVRA58%25%50%58%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ZVRA−51%−57%−34%−40%−44%−36%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 99% from December 31, 2015 to May 22, 2020. Getting back needed a 11447% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.10 – $14.75
From 52-week high
−31.5%
vs 50-day average
−9.3%
vs 200-day average
−6.1%
Volatility (1 year)
60%
Beta vs S&P 500
0.94

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±8.0%
After a week
6 up, 6 down
typical move ±6.9%
After a month
5 up, 7 down
typical move ±11.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +12.9% −0.4% +8.7% +19.2%
May 6, 2026 +3.7% +1.1% +4.8% 0.0%
March 9, 2026 +23.2% +0.7% +9.9% +6.8%
November 5, 2025 −7.2% −0.7% −4.0% −11.0%
August 12, 2025 −19.4% +1.4% −23.0% −32.1%
May 13, 2025 +5.0% +0.8% +11.1% +20.9%
April 7, 2025 −6.4% −1.7% −0.9% +6.7%
March 11, 2025 −1.0% −0.3% −0.4% −14.4%
November 12, 2024 −3.3% −0.3% +0.1% −5.8%
August 13, 2024 +2.6% +2.0% +11.5% +11.5%
August 8, 2024 −8.7% +2.8% −1.5% −0.1%
May 8, 2024 −2.8% +0.6% −6.9% −10.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Zevra Therapeutics, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Zevra Therapeutics, Inc.
$0 $50M $100M $150M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $16.6M Revenue (TTM), FY23 Q4: $27.5M Revenue (TTM), FY24 Q1: $27.7M Revenue (TTM), FY24 Q2: $23.7M Revenue (TTM), FY24 Q3: $24.5M Revenue (TTM), FY24 Q4: $23.6M Revenue (TTM), FY25 Q1: $40.6M Revenue (TTM), FY25 Q2: $62M Revenue (TTM), FY25 Q3: $84.4M Revenue (TTM), FY25 Q4: $106.5M Revenue (TTM), FY26 Q1: $122.3M Revenue (TTM), FY26 Q2: $136.1M $136.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $16.6M
FY23 Q4 $27.5M
FY24 Q1 $27.7M
FY24 Q2 $23.7M
FY24 Q3 $24.5M
FY24 Q4 $23.6M
FY25 Q1 $40.6M
FY25 Q2 $62M
FY25 Q3 $84.4M
FY25 Q4 $106.5M
FY26 Q1 $122.3M
FY26 Q2 $136.1M
Revenue growth, TTM YoY Zevra Therapeutics, Inc.
-100% 0% 100% 200% 300% 400% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 54.5% Revenue growth, TTM YoY, FY23 Q4: 170.3% Revenue growth, TTM YoY, FY24 Q1: 195.7% Revenue growth, TTM YoY, FY24 Q2: 43.2% Revenue growth, TTM YoY, FY24 Q3: 47.9% Revenue growth, TTM YoY, FY24 Q4: -14.0% Revenue growth, TTM YoY, FY25 Q1: 46.5% Revenue growth, TTM YoY, FY25 Q2: 161.8% Revenue growth, TTM YoY, FY25 Q3: 244.6% Revenue growth, TTM YoY, FY25 Q4: 350.9% Revenue growth, TTM YoY, FY26 Q1: 201.3% Revenue growth, TTM YoY, FY26 Q2: 119.4% 119.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 54.5%
FY23 Q4 170.3%
FY24 Q1 195.7%
FY24 Q2 43.2%
FY24 Q3 47.9%
FY24 Q4 -14.0%
FY25 Q1 46.5%
FY25 Q2 161.8%
FY25 Q3 244.6%
FY25 Q4 350.9%
FY26 Q1 201.3%
FY26 Q2 119.4%
Operating margin (TTM) Zevra Therapeutics, Inc.
-400% -200% 0% 200% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -264.2% Operating margin (TTM), FY23 Q4: -180.6% Operating margin (TTM), FY24 Q1: -206.6% Operating margin (TTM), FY24 Q2: -315.8% Operating margin (TTM), FY24 Q3: -354.2% Operating margin (TTM), FY24 Q4: -368.5% Operating margin (TTM), FY25 Q1: -177.1% Operating margin (TTM), FY25 Q2: -192.1% Operating margin (TTM), FY25 Q3: -103.9% Operating margin (TTM), FY25 Q4: -59.1% Operating margin (TTM), FY26 Q1: -4.4% Operating margin (TTM), FY26 Q2: 60.5% 60.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -264.2%
FY23 Q4 -180.6%
FY24 Q1 -206.6%
FY24 Q2 -315.8%
FY24 Q3 -354.2%
FY24 Q4 -368.5%
FY25 Q1 -177.1%
FY25 Q2 -192.1%
FY25 Q3 -103.9%
FY25 Q4 -59.1%
FY26 Q1 -4.4%
FY26 Q2 60.5%
FCF margin (TTM) Zevra Therapeutics, Inc.
-300% -200% -100% 0% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -133.4% FCF margin (TTM), FY23 Q4: -123.2% FCF margin (TTM), FY24 Q1: -165.7% FCF margin (TTM), FY24 Q2: -237.7% FCF margin (TTM), FY24 Q3: -284.4% FCF margin (TTM), FY24 Q4: -295.0% FCF margin (TTM), FY25 Q1: -152.3% FCF margin (TTM), FY25 Q2: -75.0% FCF margin (TTM), FY25 Q3: -28.7% FCF margin (TTM), FY25 Q4: -2.3% FCF margin (TTM), FY26 Q1: 9.8% FCF margin (TTM), FY26 Q2: 24.0% 24.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -133.4%
FY23 Q4 -123.2%
FY24 Q1 -165.7%
FY24 Q2 -237.7%
FY24 Q3 -284.4%
FY24 Q4 -295.0%
FY25 Q1 -152.3%
FY25 Q2 -75.0%
FY25 Q3 -28.7%
FY25 Q4 -2.3%
FY26 Q1 9.8%
FY26 Q2 24.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 13 13 29 10 27 24 106 136
Gross profit — — — 0 3 — 27 10 25 — — —
EBITDA −5 −16 −23 −56 −20 −5 8 −42 −49 −81 −59 84
Operating income −5 −16 −23 −56 −20 −6 8 −43 −50 −87 −63 82
Net income −5 −24 −55 −56 −25 −13 −9 −27 −46 −106 83 58
Diluted EPS −$11.73 −$3.42 −$118.72 −$50.40 −$13.23 −$3.21 −$2.11 — — −$2.28 $1.35 $0.97
Growth (year on year)
Revenue — — — — — +3.5% +115.6% −64.5% +170.3% −14.0% +350.9% +119.4%
EBITDA — — — — — — — −621.2% — — — —
Operating income — — — — — — — −650.7% — — — —
Net income — — — — — — — — — — — +>999%
Diluted EPS — — — — — — — — — — — +>999%
Margins
Gross margin — — — — 22.1% — 92.8% 97.8% 89.3% — — —
EBITDA margin — — — — −156.0% −40.2% 27.9% −409.6% −177.0% −341.4% −55.3% 61.6%
Operating margin — — — — −158.4% −42.2% 27.0% −418.9% −180.6% −368.5% −59.1% 60.5%
Net margin — — — — −191.0% −96.0% −29.9% −263.5% −167.7% −446.9% 78.2% 42.8%
Free-cash-flow margin — — — — −185.1% −14.8% 36.1% −185.1% −123.2% −295.0% −2.3% 24.0%
Cash flow
Cash from operations −4 −15 −20 −54 −24 −2 10 −19 −34 −70 −2 33
Capital spending 0 0 0 0 0 0 0 0 0 0 1 1
Free cash flow −4 −15 −20 −54 −24 −2 10 −19 −34 −70 −2 33
Stock-based pay 0 0 2 6 4 2 2 4 6 15 13 13
Free cash flow after stock pay −5 −15 −23 −61 −28 −4 8 −23 −40 −85 −15 19
Balance sheet
Cash 2 10 32 18 3 4 112 65 43 34 62 145
Total debt 0 8 9 83 80 68 0 13 43 62 64 0
Net debt (negative = net cash) −2 −3 −24 65 77 64 −112 −53 −0 28 1 −145
Diluted shares — — — 1m 2m 4m 30m 34m 35m 46m 57m 60m
Returned to shareholders
Buybacks — — — — — 0 3 5 3 0 — —
Total returned — — — — — 0 3 5 3 0 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

7 of 7 checks passed · June 30, 2026
What it owns · $303m
Short-term assets $251mLonger-term assets $51m
What it owes, and who funded it · $303m
Short-term liabilities $49mLonger-term liabilities $36mShareholders' equity $218m
  • Short-term assets cover short-term liabilities $251m of assets due within a year against $49m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $251m short-term assets against $36m of longer-dated liabilities.
  • More cash than debt $145m of cash against $0 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt No debt to cover.
  • Operating profit covers interest at least five times over Operating income of $82m against $6m of interest.

From Zevra Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+13.4%
year over year
R&D spending
11.0%
of revenue
Sales & admin spending
54.8%
of revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated ZVRA NAII NAGE HRTX ETON AMRN Median
Revenue, last 12 months $136m $143m $129m $151m $106m $176m $276m
Revenue growth, last 12 months 119.4% 9.7% 11.0% 1.0% 81.5% −22.3% 9.9%
Revenue growth, 3-year average 101.9% −2.6% 16.8% 8.6% 53.8% −18.3% 5.5%
Revenue growth, latest quarter 53.3% 1.9% −4.3% 1.3% 98.6% −20.4% 6.5%
Gross margin 89.3% 6.3% 64.2% 70.1% 57.9% 40.9% 62.0%
Operating margin 60.5% −13.2% 8.2% −7.2% 15.4% −18.2% −5.9%
Operating margin, 3-year average −149.1% −9.1% 6.6% −13.5% −2.0% −26.3% −7.4%
Net margin 42.8% −14.5% 12.4% −22.5% 12.0% −10.9% −7.3%
Cash from operations / revenue 24.5% −6.3% 4.6% −7.7% 14.3% 21.3% 10.2%
Free-cash-flow margin 24.0% −8.9% 4.2% −8.0% 14.0% 21.3% 8.6%
Free-cash-flow margin, 3-year average −96.2% −3.7% 7.4% −47.0% 11.7% 1.3% 7.4%
Stock pay / revenue 9.6% 0.4% 5.4% 7.4% 4.9% 4.2% 3.6%
Change in share count 13.4% 1.4% 2.5% 5.9% 29.1% 1.5% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 119.4% 10.0% 3 of 74
Change in growth rate Growth -81.9pp -0.3pp 70 of 74
Operating margin Profitability 60.5% -5.9% 1 of 67
Net margin Profitability 42.8% -7.3% 2 of 75
Free-cash-flow margin Cash generation 24.0% 10.1% 14 of 74
Stock pay as % of revenue Cash generation 9.6% 3.6% 54 of 69
Long-term debt as % of assets Balance sheet 0.0% 23.8% 1 of 53
Change in share count Balance sheet 13.4% 1.5% 51 of 62

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
MIPLYFFA $87.4M ▲ 765.3%
Olpruva $800,000 ▲ 700.0%

These categories overlap or exclude eliminations, so shares aren't shown.

From Zevra Therapeutics, Inc.'s 10-K filed March 9, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$668M
Institutions reporting
157
Shares held vs prior quarter
▲ 12.8%
Positions opened / closed
29 / 17

Top buyers and sellers, Q2 2026: 93 institutions bought and 57 sold ; the biggest buyer was FMR LLC (+1.7M shares) and the biggest seller Aigh Capital Management LLC (−1.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $73.3M 5.1M 11.0% ▲ 14.6%
FMR LLC $70.5M 4.9M 10.6% ▲ 53.0%
Woodline Partners LP $68.6M 4.8M 10.3% ▲ 38.7%
Nantahala Capital Management, LLC $51.6M 3.6M 7.7% ▲ 42.5%
Vanguard Capital Management LLC $37.8M 2.6M 5.7% ▲ 6.9%
State Street Corp $24.1M 1.7M 3.6% ▲ 7.7%
Geode Capital Management, LLC $22.1M 1.5M 3.3% ▲ 12.3%
D. E. Shaw & Co., Inc. $18.7M 1.3M 2.8% ▲ 54.4%
Qube Research & Technologies Ltd $17.8M 1.2M 2.7% ▲ 47.4%
Morgan Stanley $17.3M 1.2M 2.6% ▲ 1.0%
Legal & General Group PLC $17.2M 1.2M 2.6% ▲ 3.3%
Dimensional Fund Advisors LP $13.7M 959K 2.1% ▲ 72.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Zevra Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.5M 13 trades by 6 insiders · 95% under pre-set plans
Net ▼ $2.5M net selling
Insider Date Trade Shares Price Value
Mcfarlane Neil F. President and CEO October 12, 2026 Sell pre-set plan 20,000 $11.25 $224,948
Thompson Rahsaan Chief Legal & Compliance August 14, 2026 Sell pre-set plan 42,666 $11.13 $474,873
Watton Corey Michael Director August 10, 2026 Sell 12,300 $11.25 $138,375
Thompson Rahsaan Chief Legal & Compliance June 22, 2026 Sell pre-set plan 34,557 $12.68 $438,183
Thompson Rahsaan Chief Legal & Compliance May 11, 2026 Sell pre-set plan 1,794 $11.30 $20,272
Mcfarlane Neil F. President and CEO February 9, 2026 Sell pre-set plan 14,625 $8.56 $125,190
Schafer Joshua CCO February 3, 2026 Sell pre-set plan 10,500 $9.19 $96,495
Sangiovanni Timothy J. SVP, Finance & Corp Controller February 3, 2026 Sell pre-set plan 3,000 $9.18 $27,540
Mcfarlane Neil F. President and CEO February 2, 2026 Sell pre-set plan 91,000 $9.38 $853,580
Schafer Joshua CCO January 30, 2026 Sell pre-set plan 3,375 $8.83 $29,801
Quartel Adrian W Chief Medical Officer January 30, 2026 Sell pre-set plan 4,533 $8.83 $40,026
Thompson Rahsaan Chief Legal & Compliance January 30, 2026 Sell pre-set plan 4,080 $8.83 $36,026

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • March 9, 2026
  • November 5, 2025
  • August 12, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Zevra Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Zevra Therapeutics, Inc. in brief

What does Zevra Therapeutics, Inc. do?
Zevra Therapeutics, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Zevra Therapeutics, Inc.'s stock ticker?
Zevra Therapeutics, Inc. trades under the ticker ZVRA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Zevra Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Zevra Therapeutics, Inc. reported revenue of $136M, 119.4% higher than a year earlier, according to its SEC filings.
What is Zevra Therapeutics, Inc.'s free cash flow?
Zevra Therapeutics, Inc.'s free-cash-flow margin is 24.0% of revenue over the trailing twelve months, ranking 14 of the 74 pharmaceuticals companies we cover.
Who are Zevra Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., FMR LLC and Woodline Partners LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Zevra Therapeutics, Inc.'s market cap?
On November 2, 2026, Zevra Therapeutics, Inc.'s market capitalisation was about $606M, with a price-to-earnings ratio of 10.4 and net debt of -$145M. Market figures come from third-party market data and may be delayed.
How much debt does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc.'s debt-to-equity ratio is 0.0%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Zevra Therapeutics, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Zevra Therapeutics, Inc. are Natural Alternatives International Inc, Niagen Bioscience, Inc., Heron Therapeutics, Inc., Eton Pharmaceuticals, Inc. and Amarin Corp plc\uk. The side-by-side comparison below sets their revenue, margins and growth against Zevra Therapeutics, Inc.'s.
Are insiders buying or selling Zevra Therapeutics, Inc. stock?
Over the last 12 months, Zevra Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 13 sales on Form 4. The insider trading page charts every trade.
When is Zevra Therapeutics, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Zevra Therapeutics, Inc. announces its own schedule.